Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001243571 | SCV001416739 | likely benign | Nemaline myopathy 2 | 2024-09-26 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001552770 | SCV001773524 | uncertain significance | not provided | 2021-06-19 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 27535533, 26582918) |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004526096 | SCV005039346 | uncertain significance | not specified | 2024-03-13 | criteria provided, single submitter | clinical testing | Variant summary: NEB c.10589A>T (p.Gln3530Leu) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.2e-05 in 247480 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.10589A>T in individuals affected with Nemaline Myopathy 2 and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 968438). Based on the evidence outlined above, the variant was classified as uncertain significance. |
Natera, |
RCV001243571 | SCV002077113 | uncertain significance | Nemaline myopathy 2 | 2020-01-17 | no assertion criteria provided | clinical testing |